1. Scrip
  2. >>Business
  3. >>Earnings

Future For Spexis Looks Far From Secure

Swiss Biotech Launched End of 2021

 
• By Kevin Grogan

Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.

wallet
Like many biotechs, Spexis is strapped for cash • Source: Shutterstock

Spexis AG, the Swiss biotech that was only created at the end of last year through the merger of troubled Polyphor AG and EnBiotix, is already facing an uncertain future as it battles for funds to survive.

The company began life on 31 December after Polyphor, struggling after the failure of its lead cancer asset balixafortide in a late-stage trial for breast cancer, was handed a lifeline by a link-up with EnBiotix, a US-based rare disease company focused on cystic fibrosis (CF). When Spexis launched, CEO Jeffrey Wager said the firm was looking forward to "advancing an innovative R&D pipeline and to engaging in unique strategic corporate development to create long-term shareholder value

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.